<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: To evaluate the prognostic implications of the presence of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) during the induction period in children diagnosed with low risk B cell precursor <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (LR-ALL) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: In 36 children with LR-ALL treated with BFM-86 protocol, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> was studied at the end of induction by IgH and TCR delta gene analysis </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: The probabilities of disease free survival were: 52% (patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> at the end of Induction), 64% (patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> at day 15) and 100% (patients without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>CONCLUSIONS: The presence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> is a new and useful prognostic factor in LR <z:e sem="disease" ids="C0023452" disease_type="Neoplastic Process" abbrv="">childhood ALL</z:e> </plain></SENT>
</text></document>